135 related articles for article (PubMed ID: 15589603)
1. Expression of c-kit in uterine carcinosarcoma.
Menczer J; Kravtsov V; Levy T; Berger E; Glezerman M; Avinoach I
Gynecol Oncol; 2005 Jan; 96(1):210-5. PubMed ID: 15589603
[TBL] [Abstract][Full Text] [Related]
2. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
3. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
4. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
Leath CA; Straughn JM; Conner MG; Barnes MN; Alvarez RD; Partridge EE; Huh WK
J Reprod Med; 2004 Feb; 49(2):71-5. PubMed ID: 15018431
[TBL] [Abstract][Full Text] [Related]
6. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
Adams SF; Hickson JA; Hutto JY; Montag AG; Lengyel E; Yamada SD
Gynecol Oncol; 2007 Mar; 104(3):524-8. PubMed ID: 17049587
[TBL] [Abstract][Full Text] [Related]
7. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
[TBL] [Abstract][Full Text] [Related]
8. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
10. C-kit protein expression in uterine and ovarian mesenchymal tumours.
Erdogan G; Bassorgun CI; Pestereli HE; Simsek T; Karaveli S
APMIS; 2007 Mar; 115(3):204-9. PubMed ID: 17367465
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
12. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
13. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach.
Bar-Sela G; Kuten A; Ben-Eliezer S; Gov-Ari E; Ben-Izhak O
Mod Pathol; 2003 Oct; 16(10):1035-40. PubMed ID: 14559987
[TBL] [Abstract][Full Text] [Related]
14. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
Wada H; Enomoto T; Fujita M; Yoshino K; Nakashima R; Kurachi H; Haba T; Wakasa K; Shroyer KR; Tsujimoto M; Hongyo T; Nomura T; Murata Y
Cancer Res; 1997 Dec; 57(23):5379-85. PubMed ID: 9393763
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas.
Santin AD; Bellone S; Siegel ER; McKenney JK; Thomas M; Roman JJ; Burnett A; Tognon G; Bandiera E; Pecorelli S
Clin Cancer Res; 2007 Jun; 13(11):3339-46. PubMed ID: 17545541
[TBL] [Abstract][Full Text] [Related]
16. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma.
Emoto M; Charnock-Jones DS; Licence DR; Ishiguro M; Kawai M; Yanaihara A; Saito T; Hachisuga T; Iwasaki H; Kawarabayashi T; Smith SK
Gynecol Oncol; 2004 Dec; 95(3):474-82. PubMed ID: 15581949
[TBL] [Abstract][Full Text] [Related]
17. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma.
Abargel A; Avinoach I; Kravtsov V; Boaz M; Glezerman M; Menczer J
Int J Gynecol Cancer; 2004; 14(2):354-9. PubMed ID: 15086737
[TBL] [Abstract][Full Text] [Related]
18. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
20. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
